Hypothesis

Aging reduces intestinal Src family kinase (SFK) activity in ileal enterocytes, decreasing tyrosine phosphorylation of the apical sodium‑dependent bile acid transporter (ASBT). Loss of this phospho‑signal triggers ubiquitination and proteasomal degradation of ASBT, independent of total protein levels. Concurrent age‑related loss of vasoactive intestinal peptide (VIP)‑expressing nerves diminishes cAMP‑PKA signaling that normally sustains SFK activation, while elevated claudin‑2 expression leaks intracellular Na+, collapsing the electrochemical gradient required for ASBT‑mediated uptake. Together, these post‑translational and biophysical lesions produce a functional bile acid transport deficit that precedes changes in serum bile acid pools.

Mechanistic Rationale

1. SFK‑ASBT axis – Phosphorylation of ASBT tyrosine residues by Src family kinases stabilizes the transporter at the brush border Src family kinase regulation of ASBT. We hypothesize that oxidative stress and inflammation in aging suppress SFK autophosphorylation, shifting the balance toward phosphatase activity (e.g., PTP1B). Dephosphorylated ASBT is recognized by E3 ubiquitin ligases (e.g., Nedd4‑2) and targeted for proteasomal degradation, explaining the disconnect between total ASBT protein and surface activity reported in heterogeneous human cohorts Intersubject variability of ASBT protein vs mRNA.
2. VIPergic modulation – VIP activates adenylate cyclase, raising cAMP and PKA activity, which can phosphorylate and activate Src kinases VIPergic nerve degeneration in aging colon. Age‑related loss of VIP‑positive neurons in the myenteric plexus reduces this tonic support, further lowering SFK activity specifically in ileal crypts where ASBT is enriched.
3. Barrier‑gradient coupling – Increased claudin‑2–forming pores allow paracellular Na+ flux, diminishing the apical‑basolateral Na+ gradient that drives ASBT’s secondary active transport Age-related intestinal barrier dysfunction. Even if some phosphorylated ASBT remains, its turnover rate drops because the driving ion gradient is compromised.
4. Integration – The three hits (reduced SFK signaling, loss of VIP‑mediated amplification, and Na+ gradient leak) converge to produce a steep, age‑dependent decline in functional ASBT that cannot be inferred from static mRNA or total protein measures.

Testable Predictions

• Prediction 1: Ileal mucosal SFK activity (measured by kinase assay or phospho‑Src immunoblot) will be significantly lower in 24‑month versus 3‑month mice. Rescue with a Src activator (e.g., PP2 withdrawal or peptide‑based Src agonist) will restore ASBT surface expression and taurocholate uptake.
• Prediction 2: Pharmacological VIP or cAMP elevation (forskolin) will increase phospho‑ASBT levels in aged ileal segments, an effect blocked by Src inhibitor PP2, confirming VIP → cAMP/PKA → SFK → ASBT signaling.
• Prediction 3: Claudin‑2 knockdown (siRNA) or occludin overexpression in aged enterocytes will improve apical Na+ concentration (measured with SBFI dye) and enhance bile acid transport irrespective of ASBT phosphorylation state.
• Prediction 4: In vivo, aged mice treated with a Src activator plus VIP analog will show increased fecal bile acid excretion (reflecting reduced reabsorption) and improved serum FGF19 levels, indicating restored enterohepatic circulation.

Falsification: If SFK activity, ASBT phosphorylation, or VIP‑dependent signaling shows no age‑related change, or if manipulating these nodes fails to alter ASBT function or bile acid flux, the hypothesis is refuted.

Experimental Approach

• Isolation of ileal enterocytes from young and old mice; western blot for phospho‑Src (Tyr416), phospho‑ASBT (immunoprecipitated with anti‑pTyr), ubiquitinated ASBT.
• Surface biotinylation assay to quantify brush‑border ASBT.
• Uptake assays with radiolabeled taurocholate under controlled Na+ conditions.
• Nerve mapping: VIP immunostaining and electrophysiology to correlate nerve density with SFK activity.
• Claudin‑2 manipulation via CRISPRi or adenoviral shRNA in enteroid cultures.
• In vivo bile acid kinetics using labeled cholic acid and fecal metabolite profiling.

By targeting the post‑translational control hub (SFK) and its neuro‑epithelial modulators, this hypothesis shifts focus from static biomarkers to dynamic transport regulation, offering a concrete route to intervene in age‑related bile acid dyshomeostasis.